Clinically, IFIT3 expression was validated as being significantly elevated in the blood of patients with TB (including PTB and TBM) compared to healthy controls, thereby confirming its potential role as a pan-TB biomarker. This evidence concerns the gene IFIT3 and meningeal tuberculosis.